|
Study Title: A Phase III Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel or Doxorubicin Administered Every 21 Days in Women with Advanced Endometrial Cancer Who Have Previously Been Treated with Chemotherapy
What is the purpose of this study?
The purpose of this study is to compare the effectiveness of a cancer drug, called ixabepilone, to two standard chemotherapies (paclitaxel and doxorubicin) in women whose endometrial cancer has returned after having received previous chemotherapy treatment.
Am I a candidate for this study?
- Are you are age 18 or older?
- Is your endometrial cancer advanced, recurrent or metastatic?
- Has your disease come back since your last cancer treatment?
There are other eligibility requirements that can be discussed with the research team.
What do I need to do?
- First, tell your doctor about your interest in this study.
- Meet with a member of the research team to learn the details of this study.
- Agree to:
- Enter one of three treatments. You will be assigned to one of the treatments by a computer. This is called "randomization" and assures a reliable comparison of the three treatments.
- Have an EKG, and an ECHO or MUGA scan of your heart.
- Follow the study schedule, which is every 21 days for chemotherapy treatments.
- Participate in follow-up visits after receiving chemotherapy.
- Have blood tests throughout the study.
- Have CT or MRI scans as ordered by the doctor.
- Answer questions about your medical history and your experience during the study.
Why should I participate?
- This treatment may help improve your health, however there is no proof yet which treatment is more effective.
- You will help doctors learn more about which treatment is best and about the side effects of these cancer medicines. This can help future patients.
If you are interested in participating in this ovarian cancer research study, please contact:
Nancy Carothers, RN, BA, cancer research nurse coordinator
carothen@holycrosshealth.org
301-754-7921
Principal Investigator:
James Barter, MD, gynecologic oncology, obstetrics & gynecology
Co-Investigators:
Cheryl Aylesworth, MD, medical oncologist
Linda Burrell, MD, medical oncologist
Kashif Firozvi, MD, medical oncologist
Frederick D. Min, MD, medical oncologist
|
